NCT05244356 (CONVINCE) is a NA clinical trial of Health message exposure in COVID-19, sponsored by Clinical Research Centre, Malaysia.

Who is sponsoring NCT05244356?

NCT05244356 is sponsored by Clinical Research Centre, Malaysia.

What drugs are being tested in NCT05244356?

Interventions in NCT05244356: Health message exposure.

What condition does NCT05244356 study?

NCT05244356 studies COVID-19, Respiratory Disease, Vaccine Refusal, Infectious Disease, Coronavirus Infections, Behavior, Health, Pneumonia, Respiratory Tract Infections, Lung Diseases, Pneumonia, Viral.

Is NCT05244356 still recruiting?

NCT05244356 is currently completed. Last updated 17 February 2022.

Last reviewed 2022-02-17 · How we verify

NCT05244356: CONVINCE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation

Completed NA Last updated 17 February 2022

What this trial tests

NA trial testing Health message exposure in COVID-19 in 5,784 participants. Completed in 7 June 2021.

Timeline

29 April 2021

Primary endpoint
7 June 2021

7 June 2021

Quick facts

Lead sponsor	Clinical Research Centre, Malaysia
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	5,784
Start date	29 April 2021
Primary completion	7 June 2021
Estimated completion	7 June 2021
Sites	1 location across Malaysia

Drugs / interventions tested

Health message exposure

Conditions studied

COVID-19 — all drugs for COVID-19 →
Respiratory Disease — all drugs for Respiratory Disease →
Vaccine Refusal — all drugs for Vaccine Refusal →
Infectious Disease — all drugs for Infectious Disease →

Sponsor

Clinical Research Centre, Malaysia

Who can join

18 and older, any sex, with COVID-19 or Respiratory Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomised controlled experiment in the form of a web based survey study which randomly exposes participants to different forms of public health messages, after which participants will be assessed on their intent to take up the COVID-19 vaccine, recommend the vaccine, and also willingness to propagate the exposed message.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

When do persuasive messages on vaccine safety steer COVID-19 vaccine acceptance and recommendations? Behavioural insights from a randomised controlled experiment in Malaysia.
Hing NYL, Woon YL, Lee YK, Kim HJ, et al · · 2022 · cited 11× · PMID 35906015 · DOI 10.1136/bmjgh-2022-009250
When do persuasive messages on vaccine safety steer COVID-19 vaccine acceptance and recommendations? Behavioral insights from a randomised controlled experiment in Malaysia
Hing NYL, Woon YL, Lee YK, Hyung JK, et al · · 2022 · DOI 10.1101/2022.04.17.22273942

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Clinical Research Centre, Malaysia trials

Trials by the same sponsor.

NCT06293508 — mHealth Behavioural Intervention to Increase Breast Cancer Screening Rates Among Members of the Public · NA · terminated
NCT05106231 — Effectiveness of PICC Improving HBA1C and Knowledge in Diabetes Mellitus Education · NA · completed
NCT05895721 — Virtual Reality for Generalized Anxiety Disorders · NA · unknown
NCT05638919 — Real World COVID-19 Antiviral Effectiveness Research · unknown
NCT06163976 — Prognostic Modelling for Prediction of Mortality and Functional Disability in Critically-ill Elderly Patients · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05244356 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Clinical Research Centre, Malaysia
Last refreshed: 17 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05244356.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing